EXCALIBER-Maintenance
A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM)
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 3
- Enrollment
- 1,216 patients (estimated)
- Sponsors
- Bristol Myers Squibb
- Tags
- Cereblon E3 Ligase Modulators (CELMoDs), Post-Autologous Stem Cell Transplant, Randomization
- Trial Type
- Treatment
- Last Update
- 4 weeks ago
- SparkCures ID
- 1478
- NCT Identifier
- NCT05827016
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.